HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis.

ABSTRACT:

Background

Patients with Multiple Sclerosis (PwMS) display altered lipoproteins levels and function, which seem to affect disease risk and progress. Whether disease-modifying therapies affect the lipoprotein profile in PwMS has scarcely been studied.

Objective

The study aims to assess whether fingolimod and dimethyl fumarate (DMF) affect lipoproteins in PwMS.

Methods

We compared retrospectively the blood lipoprotein levels of 29 fingolimod-treated and 41 DMF-treated patients before and after 3 and 12 months of therapy. Patients treated with cholesterol-reducing medications were not included. Data on weight change and disease activity during 1-year follow-up were obtained.

Results

HDL level, HDL/LDL ratio and HDL/total cholesterol ratio were increased in both tr

SUBMITTER: Blumenfeld Kan S 

PROVIDER: S-EPMC6794658 | biostudies-literature | 2019 Oct-Dec

REPOSITORIES: biostudies-literature